Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers

Batel Blechter PhD [†,1], Xiaoyu Wang PhD [†,1], Juncheng Dai PhD [†,2,3], Christiana Karsonaki DPhil [†,4], Jianxin Shi PhD [†,1], Kouya Shiraishi PhD [†,5], Jiyeon Choi PhD [†,1], Keitaro Matsuo PhD [†,6], Tzu-Yu Chen PhD [†,7,8], Rayjean J Hung PhD, MS [†,9], Kexin Chen PhD [†,10], Xiao-Ou Shu MD, PhD [†,11], Young Tae Kim MD, PhD[12], Parichoy Pal Choudhury PhD[13], Jacob Williams PhD[1], Maria Teresa Landi MD, PhD[1], Dongxin Lin PhD[14], Wei Zheng MD, PhD[11], Zhihua Yin PhD[15], Baosen Zhou PhD[16], Jiucun Wang PhD[17,18], Wei Jie Seow PhD[19,20], Lei Song PhD[1], I-Shou Chang PhD[21], Wei Hu PhD[1], Li-Hsin Chien PhD[7,22], Qiuyin Cai PhD[11], Yun-Chul Hong PhD[23], Hee Nam Kim PhD[24], Yi-Long Wu PhD[25], Maria Pik Wong PhD[26], Brian Douglas Richardson PhD[1,27], Shilan Li PhD[1,28], Tongwu Zhang PhD[1], Charles Breeze PhD[1], Zhaoming Wang PhD, MSc[29], Bryan A Bassig PhD[30], Jin Hee Kim PhD[31], Demetrius Albanes MD[1], Jason YY Wong SM, ScD[32], Min-Ho Shin PhD[24], Lap Ping Chung PhD[26], Yang Yang PhD[33], Hong Zheng PhD[10], Hongji Dai PhD[10], Yasushi Yatabe PhD[34], Xu-Chao Zhang MD, PhD[25], Young-Chul Kim MD, PhD[35,36], Neil E Caporaso MD[1], Jiang Chang PhD[37], James Chung Man Ho MD[38], Yataro Daigo MD, PhD[39,40], Yukihide Momozawa PhD[41], Yoichiro Kamatani MD, PhD[42], Masashi Kobayashi MD, PhD[43], Kenichi Okubo MD, PhD[43], Takayuki Honda MD, PhD[44], H Dean Hosgood PhD[45], Hideo Kunitoh MD[46], Shun-ichi Watanabe MD[47], Yohei Miyagi MD, PhD[48], Shingo Matsumoto PhD[49], Hidehito Horinouchi PhD[47], Masahiro Tsuboi MD, PhD[50], Ryuji Hamamoto PhD[51], Koichi Goto MD, PhD[49], Atsushi Takahashi PhD[52], Akiteru Goto MD, PhD[53], Yoshihiro Minamiya PhD[54], Megumi Hara PhD[55], Yuichiro Nishida PhD[55], Kenji Takeuchi PhD[56], Kenji Wakai PhD[56], Koichi Matsuda PhD[57], Yoshinori Murakami MD, PhD[58], Kimihiro Shimizu PhD[59], Hiroyuki Suzuki MD, PhD[60], Motonobu Saito MD, PhD[61], Yoichi Ohtaki PhD[62], Kazumi Tanaka MD, PhD[63], Tangchun Wu MD, PhD[64], Fusheng Wei MD[65], Mitchell J Machiela ScD[1], Yeul Hong Kim MD, PhD[66], In-Jae Oh MD, PhD[67,36], Victor Ho Fun Lee PhD[68], Gee-Chen Chang PhD[69,70,71,72,73], Kuan-Yu Chen MD, PhD[74], Wu-Chou Su MD[75], Yuh-Min Chen MD, PhD[76], Adeline Seow MBBS, MD[19], Jae Yong Park MD, PhD[77], Sun-Seog Kweon PhD[24,78], Yu-Tang Gao MD[79], Jianjun Liu PhD[80,81], Ann G Schwartz PhD, MPH[82], Richard Houlston PhD[83], Ivan P Gorlov PhD[84], Xifeng Wu PhD[85], Ping Yang MD, PhD, MPH[86], Stephen Lam PhD[87], Adonina Tardon PhD[88], Chu Chen PhD[89], Stig E Bojesen PhD[90,91], Mattias Johansson PhD[92], Angela Risch PhD[93,94,95], Heike Bickeböller PhD[96], Bu-Tian Ji PhD[1], H-Erich Wichmann PhD[97,98], David C Christiani MD, MPH, MS[99], Gad Rennert MD, PhD[100], Susanne M Arnold MD[101], Paul Brennan PhD[92], James McKay PhD[92], John K Field PhD[102], Michael P.A. Davies PhD[102], Sanjay S Shete PhD[103], Loïc Le Marchand MD, PhD[104], Geoffrey Liu PhD[105], Angeline S Andrew PhD[106], Lambertus A Kiemeney PhD[107], Shan Zienolddiny-Narui PhD[108], Kjell Grankvist PhD[109], Angela Cox PhD[110], Fiona Taylor PhD[111], Jian-Min Yuan PhD[112], Philip Lazarus PhD[113], Matthew B Schabath PhD[114], Melinda C Aldrich MPH, PhD, FACE[115], Hyo-Sung Jeon PhD[116], Shih Sheng Jiang PhD[21], Chung-Hsing Chen PhD[21,117], Chin-Fu Hsiao PhD[7], Zhibin Hu PhD[2], Laura Burdett PhD[1,118], Meredith Yeager PhD[1,118], Amy Hutchinson PhD[1,118], Belynda Hicks PhD[1,118], Jia Liu PhD[1,118], Sonja I Berndt PhD[1], Wei Wu PhD[15], Junwen Wang PhD[119,120], Yuqing Li PhD[121], Jin Eun Choi PhD[122], Kyong Hwa Park MD, PhD[123], Sook Whan Sung MD[124], Chang Hyun Kang PhD[125], Wen-Chang Wang PhD[126], Jun Xu PhD[127], Peng Guan PhD[15,128], Wen Tan PhD[14], Chong-Jen Yu MD, PhD[129], Gong Yang MD[11], Alan Dart Loon Sihoe PhD[130], Yi Young Choi PhD[131], In Kyu Park MD, PhD[125], Hsiao-Han Hung MS[21], Roel C.H.

Vermeulen PhD[132], Iona Cheng PhD[121], Junjie Wu MD[133], Fang-Yu Tsai MS[21], John K.C. Chan MD[134], Jihua Li MD[135,136], Hsien-Chih Lin PhD[7,136], Jie Liu PhD[137], Bao Song PhD[137], Norie Sawada MD, PhD[138], Taiki Yamaji MD, PhD[139], Kathleen Wyatt MS[1,118], Hongxia Ma PhD[2,3], Meng Zhu PhD[2,3], Yifan Wang PhD[2,3], Tianchen Qi MS[2,3], Xuelian Li PhD[15,128], Yangwu Ren PhD[15,128], Ann Chao PhD[140], Motoki Iwasaki MD, PhD[138,139], Junjie Zhu PhD[33], Guoping Wu MD[65], Chih-Yi Chen MD[141,142], Chien-Jen Chen ScD, PhD[143], Pan-Chyr Yang MD, PhD[144], Victoria L. Stevens PhD[145], Joseph F. Fraumeni Jr PhD[1], Kuang Lin PhD[4], Robin G Walters PhD[4], Zhengming Chen DPhil[4], Nilanjan Chatterjee PhD [‡,1,146,147], Olga Y Gorlova PhD [‡,148,149,150], Christopher I Amos PhD [‡,148,149,150,151], Hongbing Shen PhD [‡,2,3], Chao Agnes Hsiung PhD [‡,7], Stephen J Chanock MD [‡,1], Nathaniel Rothman MD, MPH, MHS [‡,1], Takashi Kohno PhD [‡,5], Qing Lan MD, PhD [‡,1], Haoyu Zhang PhD [‡,1]

[1]Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA, [2]Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China, [3]Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China, [4]Nuffield Department of Population Health, University of Oxford, Oxford, UK, [5]Division of Genome Biology, National Cancer Research Institute, Tokyo, Japan, [6]Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan, [7]Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan, [8]Department of Smart Computing and Applied Mathematics, Tunghai University, Taichung, Taiwan, [9]Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada, [10]Department of Epidemiology and Biostatistics, Key Laboratory of Prevention and Control of Human Major Diseases of the Ministry of Education, Key Laboratory of Molecular Cancer Epidemiology of Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China, [11]Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN, USA, [12]Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea, [13]American Cancer Society, Atlanta, GA, USA, [14]Department of Etiology & Carcinogenesis and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, [15]Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China, [16]Department of Clinical Epidemiology and Center of Evidence Based Medicine, The First Hospital of China Medical University, Shenyang, China, [17]Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China, [18]State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Fudan University, Shanghai, China, [19]Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore, [20]Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore, [21]National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan, [22]Department of Applied Mathematics, National Dong Hwa University, Hualien, Taiwan, [23]Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, [24]Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea, [25]Guangdong Lung Cancer Institute, Guangdong

Provincial People's Hospital & Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China, [26]Department of Pathology, Queen Mary Hospital, Hong Kong, China, [27]Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA, [28]Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington DC, DC, USA, [29]Department of Epidemiology and Cancer Control (Primary) & Department of Computational Biology (Secondary), St. Jude Children's Research Hospital, Memphis, TN, USA, [30]Saville Cancer Screening and Prevention Center, Inova Schar Cancer Institute, Inova Health System, Fairfax, VA, USA, [31]Department of Integrative Bioscience & Biotechnology, Institute of Bioscience, Sejong University, Seoul, 05006, Republic of Korea, [32]Epidemiology and Community Health Branch, National Heart Lung and Blood Institute, Bethesda, MD, USA, [33]Shanghai Pulmonary Hospital, Shanghai, China, [34]Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan, [35]Lung Cancer Clinic, Pulmonary Medicine, Chonnam National University Medical School, Hwasun Hospital, Hwasun, Republic of Korea, [36]Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea, [37]School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, [38]Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China, [39]Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan, [40]Department of Medical Oncology and Cancer Center, and Center for Advanced Medicine against Cancer, Shiga University of Medical Science, Shiga, Japan, [41]Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, [42]Laboratory of Complex Trait Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan, [43]Department of Thoracic Surgery, Tokyo Medical and Dental University, Tokyo, Japan, [44]Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan, [45]Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, USA, [46]Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan, [47]Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan, [48]Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan, [49]Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan, [50]Department of Thoracic Oncology, Division of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan, [51]Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan, [52]Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, [53]Department of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita, Japan, [54]Department of Thoracic Surgery, Graduate School of Medicine, Akita University, Akita, Japan, [55]Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga, Japan, [56]Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan, [57]Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Science, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan, [58]Department of Molecular Biology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo, Japan, [59]Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine Asahi, Nagano, Japan, [60]Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan, [61]Department of Cancer Genome Medicine, Fukushima Medical University Hospital, Fukushima, Japan,

[62]Department of Integrative center of General Surgery, Gunma University Hospital, Gunma,
Japan, [63]Department of Healthcare Quality and Safety, Gunma University Graduate School of
Medicine, Gunma, Japan, [64]Dept of Occupational and Environmental Health, Key Laboratory for
Environment and Health, Ministry of Education and State Key Laboratory of Environmental
Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
China, [65]China National Environmental Monitoring Center, Beijing, China, [66]Korea University
College of Medicine Anam Hospital, Seoul, Republic of Korea, [67]Lung Cancer Center, Chonnam
National University Hwasun Hospital, Hwasuneup, Republic of Korea, [68]Department of Clinical
Oncology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China, [69]School of
Medicine and Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, [70]Lung
Cancer Diagnosis & Treatment Research Center, Chung Shan Medical University Hospital,
Taichung, Taiwan, [71]Institute of Biomedical Sciences, National Chung Hsing University,
Taichung, Taiwan, [72]Department of Internal Medicine, Division of Chest Medicine, Taichung
Veterans General Hospital, Taichung, Taiwan, [73]Department of Pulmonary and Critical Care,
Xiamen Chang Gung Hospital, Xiamen, China, [74]Department of Internal Medicine, National
Taiwan University Hospital and College of Medicine, Taipei, Taiwan, [75]Department of
Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng
Kung University, Tainan, Taiwan, [76]Department of Chest Medicine, Taipei Veterans General
Hospital, and School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan,
[77]Lung Cancer Center, Kyungpook National University Medical Center, Daegu, Republic of
Korea, [78]Jeonnam Regional Cancer Center, Chonnam National University, Hwasun, Republic of
Korea, [79]Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai
Jiaotong University, School of Medicine, Shanghai, China, [80]Lab of Human Genomics, Genome
Institute of Singapore, A*STAR, Singapore, Singapore, [81]Yong Loo Lin School of Medicine,
National University of Singapore, Singapore, Singapore, Singapore, [82]Karmanos Cancer
Institute, Wayne State University, Detroit, MI, USA, [83]Division of Genetics and Epidemiology,
Institute of Cancer Research, London, UK, [84]Department of Medicine, Section of Epidemiology
and Population Science, Institute for Clinical and Translational Research, Houston, TX, USA,
[85]School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China, [86]Department of
Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA, [87]Department of Integrative
Oncology, BC Cancer, Vancouver, BC, Canada, [88]Health Research Institute of Asturias (ISPA),
IUOPA University of Oviedo and University Nebrija, Spain, [89]Program in Epidemiology, Public
Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA, [90]Department Of
Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark, [91]Department of Clinical Biochemistry, Herlev and Gentofte Hospital,
Copenhagen University Hospital, Copenhagen, Denmark, [92]International Agency for Research
on Cancer (IARC/WHO), Lyon, France, [93]German Cancer Research Center (DKFZ), Heidelberg,
Germany, [94]Translational Lung Research Center Heidelberg (TLRC-H), Member of the German
Center for Lung Research (DZL), Heidelberg, Germany, [95]Department of Biosciences and
Medical Biology and Center for Tumorbiology and Immunology (CTBI), University of Salzburg
and Cancer Cluster Salzburg, Salzburg, Austria, [96]University Medical Center Goettingen,
Goettingen, Germany, [97]Institute of Medical Informatics, Biometry and Epidemiology, Ludwig
Maximilians University, Munich, Germany, [98]Helmholtz Center Munich, Institute of
Epidemiology, Munich, Germany, [99]Harvard TH Chan School of Public Health, Boston, MA,
USA, [100]Technion-Israel Institute of Technology and APRPM, Haifa, Israel, [101]Markey Cancer
Center, Lexington, KY, USA, [102]University of Liverpool, Liverpool, UK, [103]The University of

Texas, MD Anderson Cancer Center, Houston, TX, USA, [104]Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA, [105]Princess Margaret Cancer Center, Toronto, ON, Canada, [106]Norris Cotton Cancer Center, Lebanon, NH, USA, [107]Radboud University Medical Center, Nijmegen, The Netherlands, [108]National Institute of Occupational Health, Oslo, Norway, [109]Department of Medical Biosciences, Umeå University, Umeå, Sweden, [110]Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK, [111]University of Sheffield, Sheffield, UK, [112]UPMC Hillman Cancer Center and Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA, [113]Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, SUNY University at Buffalo, NY, USA, [114]Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, [115]Department of Medicine, Division of Genetic Medicine and Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA, [116]Cancer Research Center, Kyungpook National University Medical Center, Daegu, Republic of Korea, [117]Department of Mathematics, University of Taipei, Taipei, Taiwan, [118]Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc, Rockville, MD, USA, [119]Division of Applied Oral Sciences & Community Dental Care, Faculty of Dentistry, The University of Hong Kong, Hong Kong, China, [120]State Key LaState Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China, [121]Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA, [122]Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea, [123]Department of Internal Medicine, Division of Oncology/Hematology, College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea, [124]Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, [125]Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea, [126]The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, [127]School of Public Health, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, China, [128]Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang, China, [129]Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan, [130]Gleneagles Hong Kong Hospital, Hong Kong, China, [131]Cancer Research Center, Kyungpook National University Medical Center, Daegu, Republic of Korea, [132]Division of Environmental Epidemiology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands, [133]Department of Pulmonary and Critical Care Medicine Zhongshan Hospital, Fudan University Shanghai Geriatric Medical Center, Shanghai, China, [134]Department of Pathology, Queen Elizabeth Hospital, Hong Kong, China, [135]Qujing Center for Diseases Control and Prevention, Qujing, China, [136]State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China, [137]Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, China, [138]Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokyo, Japan, [139]Division of Epidemiology, National Cancer Center Institute for Cancer Control, Tokyo, Japan, [140]Center for Global Health, National Cancer Institute, Bethesda, MD, USA, [141]Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, [142]Department of Surgery, Division of Thoracic Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan, [143]Genomic Research Center, Academia Sinica, Taipei, Taiwan, [144]Department of Internal Medicine,

National Taiwan University Hospital, Taipei, Taiwan, [145]Laboratory Services, American Cancer Society, Georgia, USA, [146]Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA, [147]Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, [148]Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA, [149]Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, TX, USA, [150]Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA, [151]University of New Mexico, Comprehensive Cancer Center, Albuquerque, NM, USA

[†] These authors contributed equally to this work

[‡] These authors jointly directed this work

Correspondence to:

Batel Blechter

National Cancer Institute

9609 Medical Center Drive, Room 6E124

Rockville MD, 20850, USA

Email: batel.blechter@nih.gov

Abstract

Background

Lung adenocarcinoma (LUAD) in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve LUAD risk prediction.

Methods

PRSs were developed using genome-wide association study summary statistics from East Asian (8,002 cases; 20,782 controls) and European (2,058 cases; 5,575 controls) populations. Single-ancestry models included PRS-25, PRS-CT, and LDpred2; multi-ancestry models included LDpred2+PRS-EUR128, PRS-CSx, and CT-SLEB. Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium (FLCCA) and externally validated in the Nanjing Lung Cancer Cohort (NJLCC). We assessed predictive accuracy via AUC, with 10-year and (age 30-80) absolute risks estimates.

Results

The best multi-ancestry PRS, using East Asian and European data via CT-SLEB (clumping and thresholding, super learning, empirical Bayes), outperformed the best East Asian-only PRS (LDpred2; AUC=0.629, 95% CI:0.618,0.641), achieving an AUC of 0.640 (95% CI:0.629,0.653) and odds ratio of 1.71 (95% CI:1.61,1.82) per SD increase. NJLCC Validation confirmed robust performance (AUC =0.649, 95% CI: 0.623, 0.676). The top 20% PRS group had a 3.92-fold higher LUAD risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69%

lifetime absolute risk. Notably, this group reached the average population 10-year LUAD risk at

age 50 (0.42%) by age 41, nine years earlier.

Conclusions

Multi-ancestry PRS approaches enhance LUAD risk stratification in East Asian never-smokers,

with consistent external validation, suggesting future clinical utility.

Key Words: Polygenic risk scores, Lung adenocarcinoma, Genome-wide association studies,

East Asian never smokers, Lifetime absolute risk

Abbreviations:

LUAD, lung adenocarcinoma; GWAS, genome-wide association study; EUR, European; PRS,

polygenic risk score; SNP, single nucleotide polymorphism; FLCCA, Female Lung Cancer

Consortium in Asia; LD, linkage disequilibrium; AUC, area under the receiver operating curve;

PC, principal component; OR, odds ratio; CI, confidence interval; USPSTF, United States

Preventive Services Taskforce

Introduction

Lung cancer is a major global health challenge, responsible for about 20% of all cancer deaths in 2020[1]. While smoking is the primary etiologic factor, around 25% of lung cancer cases occur in never-smokers, with significant geographical variations[2] . Notably, in East Asia, never-smoking women exhibit high incidences of lung adenocarcinoma (LUAD), the predominant histologic subtype[3].

Beyond smoking, risk factors for LUAD include environmental and occupational exposures, lifestyle, family history, and genetic susceptibility[4–7]. Genome-wide association studies (GWAS) for never-smoking lung cancer across East Asian and European (EUR) populations have identified 28 susceptibility loci at 25 independent regions[8–13]. These GWAS findings enhance our understanding of LUAD's genetic architecture; yet, the translation of these findings into clinical applications requires further investigation.

Polygenic risk scores (PRS) aggregate the effects of individual common single nucleotide polymorphisms (SNPs) to estimate genetic risk for diseases, potentially playing a role in cancer prevention and screening. Previous efforts primarily utilized European populations for lung cancer PRS development[14,15] to better identify high-risk individuals. Nonetheless, because of differences in linkage disequilibrium and allele frequencies across ancestries, such PRSs often underperform in East Asian never-smokers, reflecting the need to address the disproportionate burden of LUAD in this population and to advance the integration of PRS into risk stratification for lung cancer prevention and screening. Despite ongoing efforts to integrate PRS into clinical practices for complex diseases, as seen in initiatives like the electronic Medical Records and Genomics (eMERGE) network[16], Veterans Affairs Genomic Medicine at Veteran Affairs (GenoVA) study[17], and the Women Informed to Screen Depending On Measures of risk

(WISDOM) study[18], lung cancer has been excluded. The predominant global burden of lung

cancer, driven primarily by smoking, overlooks the significant impact and potential benefits of

PRS in never-smoking populations.

The recent expansion of GWAS across diverse populations, combined with

advancements in PRS methodology, underscores a pivotal shift towards enhancing disease

outcome prediction beyond European populations[19]. Notably, the development of multi-ancestry

PRS methods marks a considerable advancement, leveraging data from various ancestral

backgrounds to enrich the predictive accuracy and robustness of PRSs[20–26]. By jointly modeling

genetic data from multiple populations, these approaches improve the predictive power of PRSs,

thereby enhancing disease outcome predictions in non-European populations.

While the development and validation of PRSs are critical, the application of an

established PRS in estimating the absolute risk of a disease offers valuable potential for risk

stratification, potentially guiding clinical interventions, such as lung cancer screening. Moreover,

projecting necessary sample sizes for future studies to achieve varying levels of PRS predictive

accuracy is an underexplored area that could significantly impact epidemiological research

design and cost-effectiveness.

This study aims to evaluate the predictive performance of single- and multi-ancestry

PRSs for LUAD in never-smoking East Asian individuals using state-of-the-art methodologies.

By integrating multiple datasets, we constructed PRSs based on summary statistics for 5,622

never-smoking cases and 21,813 never-smoking controls from East Asian and European

ancestries. We assessed the performance of these PRSs using independent, individual level data

of 4,438 never-smoking East Asian cases and 4,544 never-smoking East Asian controls.

Furthermore, we estimated the lifetime and 10-year absolute risks of LUAD using the most

accurate PRSs developed. Lastly, we projected the sample sizes needed in future research to

achieve specific levels of prediction accuracy with PRSs in East Asian never-smokers (**Figure**

1).

Methods

Study design and data sources

<u>Training data compilation: study population and genotyping</u>

The studies, genotyping protocols, and quality control for PRS construction have been

previously described in detail[27]. Briefly, biological sex and main continental ancestry were

genetically determined for all participants in each study. East Asian single-ancestry PRSs for

LUAD were constructed using summary data from 3,564 never-smoking LUAD cases and

16,238 never-smoking controls of East Asian ancestry from the Nanjing Lung Cancer Cohort

(NJLCC)[28–31], National Cancer Center of JAPAN (NCC), and the Research Institute and Aichi

Cancer Center (ACC). The NJLCC study combined data from several cities, genotyped by

Affymetrix Genome-Wide Human SNP Array 6.0, Illumina OncoArray, Illumina Asian

Screening Array, as well as whole genome-sequecing by Illumina HiSeq or NovaSeq

platforms[28–31].The NCC study included lung cancer patients and control data from multiple

Japanese studies, with genotyping conducted on Illumina HumanOmniExpress and

HumanOmni1-Quad genotyping platforms. Similarly, the ACC study pooled data from multiple

Japanese medical institutions and the Nagahama Study, with genotyping performed using

Illumina 610k and Illumina660k platforms. Imputation and quality control were conducted using

the pipeline described in Shi et al. (2023)[27]. SNPs with minor allele frequency < 0.01, Hardy-

Weinberg Equilibrium p-value 1.0×10^{-6} , or imputation quality scores < 0.5 were excluded.

Genotype imputation was performed using IMPUTE2 and the 1000 Genomes Project East Asian

samples (Phase 3) as the reference panel. Variants present in the training datasets (NJLCC, NCC,

and ACC) but not in the validation dataset (FLCCA) were excluded from analyses. To construct

the multi-ancestry PRS, we further incorporated GWAS summary statistics from 2,058 never-

smoking LUAD cases and 5,575 never-smoking controls of European ancestry, genotyped using

Illumina Infinium OmniExpress-24 v1.2 BeadChips and Illumina Human660W-Quad

BeadChip[13]. Weights for all East Asian single-ancestry PRSs and the East Asian portion of the

multi-ancestry PRSs were estimated from a meta-analysis restricted to never-smokers from

NJLCC, NCC and ACC studies.

<u>Tuning and validation: study population and genotyping</u>

For PRS tuning and internal validation, we used 4,438 never-smoking LUAD cases and

4,544 never-smoking controls from the Female Lung Cancer Consortium in Asia (FLCCA)[10,11],

an international consortium composed of never-smoking East Asian women from regions

including Mainland China, Singapore, Taiwan, Hong Kong, South Korea and Japan [10,11]. All

samples were genotyped using the Illumina 660W, 370K or 610Q microarrays. Biological sex

and ancestry were genetically determined, and information on age and family history of lung

cancer were collected through a questionnaire. The FLCCA data were randomly and equally

divided for tuning (2,219 cases, 2,272 controls) and validation (2,219 cases, 2,272 controls).

We externally validated the PRSs in two independent studies, including the NJLCC-

WGS[29] and the China Kadoorie Biobank (CKB). The NJLCC-WGS is a subproject of NJLCC,

aiming to identify rare variants of lung cancer by whole-genome sequencing. In the NJLCC-

WGS, 1,643 never-smoking LUAD cases (473 male; 1,170 female) and 2,235 never-smoking

controls (795 male; 1,440 female) were sequenced by the Illumina HiSeq or NovaSeq platforms.

The alignment, genotyping and quality control are previously described in detail[29]. Briefly, the

sequencing data from each individual were jointly genotyped for high confidence alleles using

GATK v3.8 according to the best practice. SNPs with inbreeding coefficients < -0.3, proportions

of samples with high genotype-quality (GQ) ($\geq$20) $\leq$ 0.8, proportions of samples with enough

sequencing depth ($\geq$10) $\leq$ 0.8, call rates $\leq$0.95 and Hardy-Weinberg Equilibrium p-value

1.0×10^{-4} were excluded.

The CKB is a population-based prospective cohort of 512,639 adults recruited between

2004 and 2008 from 10 geographical regions in China[32,33]. Due to limited histology information,

analyses in CKB were conducted using all never-smoking lung cancer cases (71 males; 458

females) rather than LUAD-specific cases. Genotyping was performed on these cases and 47,601

never-smoking controls (4,662 male; 42,939 female) using custom Affymetrix (now

ThermoFisher) Axiom® genotyping array with improved genome-wide coverage of common

and low-frequency variation in Chinese populations. The sample call rate threshold was 95%,

and the variant call rate threshold was 98%. Genotypes were imputed using the TOPMed

reference panel. We used the imputed genotypes with imputation INFO > 0.3.

Informed consent was obtained from all participants, and the recruitment and data

collection procedures were approved by the local ethics review committees of all participating

research institutes.

Construction of PRS

<u>Single-ancestry PRS methods</u>

PRS-25: We constructed a simple PRS using the 25 independent SNPs (PRS-25) that

reached genome-wide significance (i.e., $P<5\times10^{-8}$) in the largest GWAS for LUAD in East Asian

population to date (**Data S1**)[8]. The PRS-25 was calculated by summing the risk alleles weighed

by their effect sizes (i.e., per allele log-odds ratio) obtained from a meta-analysis including only

never-smokers. We note of the 25 SNPs previously identified, rs4268071 (MAF = 0.04) was not

available in FLCCA, which we replaced with a SNP in high LD (r^2=0.84), rs4266592.

PRS-CT: We generated a PRS using the CT method[34] using PLINK 1.90[35]. This

involved the clumping of SNPs based on linkage disequilibrium (LD) with a threshold of r^2=0.1

within a 500kb window **Data S1**). The LD were estimated from half of the FLCCA dataset used

for tuning dataset. We created nine SNP subsets by applying incremental P-value thresholds (i.e.,

$P<5\times10^{-8}$, $P<5\times10^{-7}$,…, $P<5\times10^{-1}$, 1), and calculated their respective PRSs using PLINK2[35]

command "--score cols=+scoresums,-scoreavgs no-mean-imputation". Using the tuning dataset,

the AUC was calculated for each threshold to identify the most predictive P-value cutoff.

LDpred2-PRS: We applied the LDpred2 method, implemented in the R package

bigsnpr[36], using a Bayesian framework to estimate SNP effect sizes through a shrinkage

estimator (**Data S1**). This method leverages GWAS summary statistics, incorporating a prior for

effect sizes, while also accounting for LD across SNPs. Our analysis was constrained to

HapMap3 variants, and we calibrated the model using a range of hyperparameters: the

proportion of causal SNPs was set across a 21-point logarithmic sequence from 10^{-5} to 1 , and

the per-SNP heritability was set as a fraction (0.3, 0.7, 1 or 1.4) of the total heritability estimated

by LD score regression[37] divided by the number of causal SNPs. Lastly, we used the "sparse"

option to set weaker effects to zero. The optimal tuning parameters were selected based on the

highest AUC achieved on the tuning dataset.

PRS-EUR 128: We evaluated the performance of a European-derived PRS (PRS-EUR

128)[38], which consists of 128 variants (**Data S1**) obtained from a GWAS of predominately active

smokers, on East Asian populations to assess its cross-population applicability. We note that the

largest GWAS conducted in European never-smokers to date have only identified a single region

(*TERT/CLPTM1L*) in which SNPs reached genome-wide significance[39], limiting the scope of a

potential targeted PRS.

<u>Multi-ancestry PRSs methods:</u>

LDpred2 PRS + PRS-EUR 128: For the multi-ancestry PRSs, we applied the weighted-

PRS approach by linearly combining the most predictive single-ancestry PRS from the East

Asian population (Ldpred2 PRS) with the European population-specific PRS (PRS-EUR 128)

(**Data S1**). The weights of this combined PRS were calculated by applying a logistic regression

on the tuning dataset in R version 4.2.0.

PRS-CSx: We applied PRS-CSx, a multi-ancestry polygenic prediction method that uses

a Bayesian framework with a continuous shrinkage prior to estimate SNP effect sizes from

GWAS summary statistics across different populations[26]. LD reference panels for European and

East Asian, provided by the PRS-CSx software, were constructed from the 1000 Genomes

Project (1KG) samples [40]. We used the default setting with the gamma-gamma prior

hyperparameters (a and b) at 1 and 0.5, respectively. The shrinkage parameter ϕ was assessed at

10^{-6}, 10^{-4}, 10^{-2}, and 1 within the tuning dataset to select the value with highest AUC. With the

optimal ϕ , we calculated the PRS using posterior effect-sizes from both East Asian and

European populations. Weights were then estimated to linearly combine the two PRSs on the

tuning dataset (**Data S1**). The final performance was then evaluated on an East Asian

independent validation dataset.

CT-SLEB: We used the recently developed CT-SLEB (clumping and thresholding, super

learning, and empirical Bayes) method to derive a PRS using East Asian and European datasets

[24]. This method extends the standard CT method by designing a two-dimensional approach to

select SNPs for East Asian PRS construction. It incorporates an empirical Bayesian (EB)

framework to model genetic correlations between East Asian and EUR. Following this, a super

learning (SL) model is then applied to integrate multiple PRSs, each generated using distinct p-

value thresholds and clumping parameters[37]. Our implementation of CT-SLEB followed the

default setting with p-value thresholds $p_t = 5\text{x}10^{-8}, 5\text{x}10^{-7}, ..., 5\text{x}10^{-1}$, or 1, and genetic

distances $d = 50/r^2$ or $100/r^2$, where $r^2 = 0.01, 0.05, 0.1, 0.2, 0.5 \text{ } or \text{ } 0.8$. The clumping

process for East Asian was based on the LD reference derived from the FLCCA tuning dataset,

and the European LD reference was based on the 1KG European samples.

Relative and absolute risk calculation for PRSs

To evaluate each PRS's performance, we standardized the scores to a unit standard

deviation, based on the distribution among the control group in the East Asian validation dataset.

We then quantified the association between the standardized PRSs and LUAD risk using the OR

and 95% CI, via logistic regression, adjusting for age and the first 10 principal components

(PCs). We evaluated the predictive performance of the different PRS models through the

adjusted AUC values, accounting for age and top 10 PCs, using the R package RISCA[41]. We

further estimated the ORs of each PRS for risk of LUAD based on PRS percentiles, setting the

middle quantile (40-60%) as the reference category. Lastly, we used the likelihood ratio test to

evaluate the interaction between the PRS and age (<40, 40-49, 50-59, 60-69, ≥70). Statistical

tests performed were two-sided and an alpha<0.05 was considered noteworthy.

For absolute risk estimates, we used the iCARE software[42] to calculate the cumulative

lifetime (age 30-80) and 10-year absolute risks of LUAD among never-smoking female controls

in FLCCA (N=4,544). Absolute risks were derived by applying the Cox proportional hazard

model with the top performing PRS (CT-SLEB) and age-specific lung cancer incidence and

mortality rates in Taiwan[43]. We chose to use incidence rates from Taiwan as approximately a

quarter of FLCCA samples are from Taiwan, and most individuals in Taiwan are Han Chinese,

similar to those in Mainland China. Notably, the lung cancer rates available for Taiwan are

specifically for never-smokers, which makes for more appropriate estimate of absolute risks that

may otherwise be inflated if ever smokers are included in the reported rates. We estimated the

absolute risk of LUAD overall, as well as stratified by first-degree family history of lung cancer.

Projections of CT and LDpred2 PRS performance by sample size

We used GENESIS package [44] to estimate the sample sizes needed for PRS to reach

various AUC levels in the East Asian population. This method estimates the expected number of

SNP discoveries and their explained heritability in future studies. Using the GWAS summary

statistics from our East Asian training dataset, and the provided LD scores for East Asian

populations from the 1KG dataset, we projected the AUC for CT PRS across various case-

control ratios, from 1:1 to 1:10, and case numbers ranging from 5,000 to 200,000. Given

GENESIS's specific design for CT PRS, we extended its application to LDpred2 PRS

projections. This involved modeling the relationship between effective sample sizes with the

phenotypic variance ratio between LDpred2 and CT PRS (**Figure S1)**, elaborated in

Supplementary Methods.

Results

Development and validation of the PRS

We applied several cutting-edge single-and multi-ancestry PRS methods (**Methods,**

Figure S2), evaluating their performance in terms of relative risk and AUC within the FLCCA

dataset of East Asian female never-smokers (**Methods**, **Table 1, Figure S2-S3)**. Among single-

ancestry PRS methods, the LDpred2 PRS, incorporating 942,591 SNPs, outperformed other

methods, with an odds ratio (OR) per unit standard deviation (SD) of 1.62 (95% confidence

interval (CI): 1.52, 1.73) alongside an adjusted AUC of 0.629 (95% CI: 0.618, 0.641). In

contrast, the PRS designed exclusively for European populations underperformed in our East

Asian population, with an estimated adjusted AUC of 0.489 (95% CI: 0.477, 0.501), possibly

attributed to the inclusion of smokers in the development of the existing European PRS.

Among multi-ancestry PRS methods, the weighted-PRS of East Asian and European

yielded an OR per unit SD of 1.62 (95% CI: 1.52, 1.72), with PRS-CSx and CT-SLEB showing

even stronger association with ORs of 1.67 (95% CI: 1.57, 1.78) and 1.71 (95% CI: 1.61, 1.82),

respectively. Among all the PRS methods, CT-SLEB had the highest AUC of 0.640 (95% CI:

0.629, 0.653). Setting individuals in the middle PRS quantile (40th to 60th percentile) as the

reference category, those in the highest 5% of risk for the top performing PRS, CT-SLEB, had

4.17 (95% CI: 3.20, 5.47)-fold risk, whereas those in the lowest 5% had 0.33 (95% CI: 0.21,

0.51)-fold risk of developing LUAD (**Figure 2**).

We further evaluated the PRSs in independent external datasets of male and female

never-smokers from NJLCC and CKB**.** Similar to our findings in FLCCA, we observed the

LDpred2 PRS had moderate performance among the single-ancestry PRS methods with an OR of

1.77 (95% CI: 1.61, 1.95) and an adjusted AUC of 0.645 (95% CI: 0.615, 0.672) in NJLCC

female never-smokers (**Table 2**). Among the multi-ancestry PRS methods, CT-SLEB yielded an

OR of 1.85 (95% CI: 1.68, 2.04) and an AUC of 0.649 (95% CI: 0.623, 0.678). Notably, among

male never-smokers, LDpred2 PRS yielded the highest relative risk estimate (OR=1.91, 95% CI:

1.66, 2.21) and AUC value (AUC=0.669, 95% CI: 0.633, 0.705) among both the single- and

multi-ancestry PRSs. However, the estimates for the different PRS approaches were not

statistically different. PRS performance in CKB was lower than in FLCCA and NJLCC, likely

due to small sample size and inablility to restrict analyses to LUAD cases only. Specifically,

across both the single- and multi-ancestry PRSs, PRS-25 showing the highest performance in

male (OR=1.29, 95% CI: 1.02, 1.63; AUC=0.611, 95% CI: 0.547, 0.673) and female (OR=1.25,

95% CI: 1.14, 1.37); AUC=0.572, 95% CI: 0.542, 0.606) never-smokers (**Table S1)**. However,

the validation was conducted among lung cancer cases with all histological subtypes, which may

have limited the performance of the PRSs developed for LUAD.

Interaction between CT-SLEB PRS and age

We observed a statistically significant multiplicative interaction between the CT-SLEB PRS and

age at diagnosis for LUAD risk (p-interaction = 0.002, **Figure 3**, **Table S2**), with risk estimates

increasing across middle-age categories (40-69) and peaking between ages 60-69 (OR = 1.93,

95% CI: 1.79-2.08). Individuals under 40 also exhibited an elevated PRS-associated risk (OR =

1.70, 95% CI: 1.42, 2.05). However, while an external validation in NJLCC was suggestive of an

interaction (p-interaction = 0.07), the risk estimates followed a steady increasing trend with age,

reaching the highest OR in individuals 70 and older (OR = 2.04, 95% CI: 1.64-2.58). When

stratified by sex, NJLCC results were further attenuated. External validation in CKB also did not

confirm an interaction between the PRS and age at diagnosis (p-interaction=0.27). While

findings in FLCCA suggest a potential age-related variation in PRS effects, the lack of statistical

significance in NJLCC and CKB indicates that this relationship may not be robust. Additional

studies with larger sample sizes are needed to determine whether PRS effects on LUAD risk

truly differ by age.

Absolute risk of developing lung adenocarcinoma by CT-SLEB PRS

Using the iCARE package[45], we estimated the absolute risk of LUAD for never-smoking

East Asian women, utilizing the CT-SLEB PRS which demonstrated the highest AUC (**Table 1**).

The cumulative lifetime risk of LUAD, assessed between age 30-80, varied markedly across PRS

percentiles, ranging from a minimal mean of 0.78% in the 5th percentile to a substantial mean of

6.69% in the 95th percentile (**Figure 4)**. Additionally, the 10-year absolute risk for LUAD in

never-smoking 50-year-old women, varied from a mean of 0.13% in the 5th percentile to mean

of 1.11% in the 95th percentile of the PRS distribution. While the average 10-year absolute risk

for this age group is 0.42%, never-smoking women in the >95 and 90-95th percentiles PRS

reached this risk earlier, at age of 41 and 42, respectively.

To evaluate the combined effect of PRS and family history, we further modeled the

absolute risk for LUAD in individuals with (n=86) and without (n=1,414) family history of lung

cancer in a first-degree relative (**Figure S4, Figure S5**). We observed that those with family

history of lung cancer have higher absolute lifetime risk of LUAD than those without family

history. The lifetime absolute risk between age 30-80 for women at the bottom 5th and top 95th

percentile of the PRS with family history of lung cancer were 2.77% and 9.39%, respectively

(**Figure S4**). Additionally, the 10-year absolute risk for women in the 95th PRS percentile with a

family history reached the population average 10-year absolute risk at age 50 (0.42%) much

earlier, at age 38. Formal tests for interaction between PRS and family history were not

statistically significant (p=0.45), suggesting that family history and PRS independently

contribute to LUAD risk stratification.

Projections of polygenic risk score performance by sample size

Using the GENESIS model, we projected the expected AUC of PRS-CT and LDpred2

PRS under varying GWAS sample sizes and case-control ratios for LUAD in never smoking East

Asian women (**Figure 5**). Our analysis, using the East Asian training dataset, estimated

approximately 1,772 (s.e.=1,641) susceptibility variants that are independently associated with

LUAD[27]. This high number of variants underscores the extensive polygenic nature of LUAD,

implying relatively small effect sizes for individual SNPs. Based on our current data, the

expected AUC for the LDpred2 PRS stands at 0.631 (95% CI: 0.618, 0.641), aligning closely

with the actual performance of the LDpred2 PRS in the validation dataset. The upper boundary

of our predictions, based solely on PRS, suggests an AUC potential of up to 0.731 (95% CI:

0.640,0.786). As sample sizes increase in our projections, the AUC is estimated to rise to 0.673

(95% CI: 0.593–0.725) with 55,000 East Asian LUAD cases and a 1:1 case-control ratio. With

the same number of cases but a 1:10 case-control ratio, the AUC is projected to further increase

to 0.698 (95% CI: 0.621–0.727), nearing the theoretical upper limit of predictive accuracy.

Explaining genetic variance through PRS across different sample sizes

We also evaluated the genetic variance explained by the PRS under different sample sizes

given the projected results (**Supplementary Methods, Table 3**). The current LDpred2 PRS

explained 26.6% of the genome-wide chip heritability, contributing to approximately 16.5% of

the 1.84-fold familial relative risk for lung cancer among East Asian never-smokers.

Concurrently, genome-wide chip variants heritability explained 61.9% of the 1.84-fold familial

relative risk associated with the disease. With an expanded sample size of 35,000 cases and

350,000 controls, the constructed PRS is projected to account for 57.9% of the genome-wide

chip variants heritability, and 35.8% of the 1.84-fold familial relative risk for the disease.

Discussion

We developed and validated single- and multi-ancestry PRSs for LUAD in never-

smoking East Asian individuals using the largest GWAS dataset of never-smokers to date. The

multi-ancestry PRS method, CT-SLEB, integrating summary data from East Asian and European

never-smokers, emerged as the best-performing PRS among female never-smokers in FLCCA

and NJLSC. It exhibited a dose-response relationship with LUAD risk and achieved higher AUC

than all other evaluated PRSs. Further, our analysis demonstrates the potential of PRS in

stratifying individuals' 10-year and lifetime risk of developing LUAD. Lastly, we projected the

expected discriminatory accuracy of the PRS across a range of sample sizes and case-control

ratios.

To date, GWAS and subsequent PRS models have largely centered on European

populations [46,47], rendering them less precise when applied to non- European populations and

risking the exacerbation of health disparities [48,49]. Consistent with prior research [15], our study

observed that a lung cancer PRS constructed using European data, which included both smokers

and never-smokers, significantly underperformed when applied to East Asian never-smoking

individuals (AUC = 0.489, 95% CI: (0.477, 0.501)), further highlighting the heterogeneity of the

disease across populations and the need to expand risk assessment efforts to non- European

populations. Notably, by utilizing novel methods to integrate GWAS data from both European

and East Asian populations, we demonstrated that a multi-ancestry PRS enhances the precision

of risk stratification for LUAD among East Asian never-smokers.

Large-scale efforts to integrate PRS into clinical practice have focused on conditions with

well-established PRS prediction performance[16–18], such as Type 2 Diabetes, breast cancer, and

cardiovascular diseases. Lung cancer has been notably absent from these efforts, primarily due to

the focus on smoking as a risk factor. This has limited the exploration and application of PRS in

lung cancer risk stratification, particularly among never-smokers. Recent efforts, such as the

TALENT study in Taiwan[50], have evaluated low-dose computed tomography (LDCT) screening

for never-smokers with traditional risk factors like family history, passive smoking exposure, and

chronic lung diseases. However, a PRS has not yet been integrated into investigated screening

protocols. Further, a recent study in Taiwan incorporating genetic susceptibility in a risk model

with lifestyle and environmental risk factors observed an improvement in the AUC from 0.697 to

0.714[43]. Notably, the study found that even by incorporating only 11 susceptibility loci, the

model's discriminative power had improved. Our study demonstrates the potential of a genome-

wide PRS to complement these efforts, enhancing risk stratification and identifying high-risk

individuals at younger ages, who may benefit from earlier interventions.

We address this gap by presenting a PRS that is associated with a 3.92-fold increase in

lung cancer risk for individuals in the top 20% risk quantile, a marked improvement over the

2.09-fold increase observed in a prior study by Wei et al. [51] for a cohort of Chinese never-

smoking women. Further, we evaluated the interaction between the PRS and age in FLCCA,

NJLCC and CKB. The relationship between the PRS and age at diagnosis showed inconsistent

patterns across datasets. In FLCCA, PRS effects varied nonlinearly, peaking at ages 60-69 and

remaining elevated in younger individuals, suggesting a potential age-related interaction.

However, NJLCC showed a gradual increase in PRS-associated risk across age groups, and

estimates in CKB did not follow a specific patter. In both studies, the interaction was not

statistically significant. This discrepancy may reflect differences in sample size, population

structure, or environmental exposures, which could influence genetic risk expression across age

groups. Future studies should examine PRS-age interactions across diverse East Asian

populations, considering additional risk factors such as environmental and hormonal influences.

667   We estimated the lifetime and 10-year absolute risk of LUAD using the PRS, which can

be used in risk stratification efforts and to identify those who are at high risk for the disease.

Specifically, we found that the 10-year absolute risk for LUAD in a never-smoking 50-year-old

woman, a critical age for initiating recommended annual lung cancer screening as per the United

States Preventive Services Taskforce (USPSTF)[52], varied from 0.13% in the 5th percentile to

1.11% in the 95th percentile of the PRS distribution. Notably, women in the highest risk

categories (>95th and 90-95th percentiles) reached the average 10-year absolute risk (0.42%)

much earlier, at ages 41 and 42, respectively. This finding suggests that the PRS has the potential

to identify younger women who may benefit from earlier risk-based interventions. While limited

in sample size, we also found that the lifetime absolute risk of LUAD was even higher among

women in the top percentile of the PRS and with first-degree family history of lung cancer,

suggesting the two risk factors may act independently for their effect on LUAD risk. Although

the absolute risk values are modest, the PRS's ability to stratify women into higher-risk

categories at younger ages suggests potential utility in guiding early screening decisions. Early

identification through PRS could be particularly valuable for never-smoking individuals, who are

traditionally excluded from lung cancer screening programs.

683   The CT-SLEB method's improved performance can be attributed to its ability to utilize

diverse genotyping arrays, thereby including population-specific variants. This aspect, along

with the inclusion of European samples in the training set, broadens the genetic diversity and

leverages larger sample sizes for improved model accuracy. Moreover, CT-SLEB excels in

modeling genetic correlations across ancestries, efficiently using both shared and unique genetic

markers for refined disease risk estimations across populations. Lastly, we set up our study with

a robust three-sample split design, dividing datasets into training, tuning, and validation. This

ensures that PRS efficacy is validated independently, effectively reducing the overfitting risk.

691   Current PRS studies predominantly focus on evaluating relative and absolute

risks[8,12,15,51,53], yet our research introduces a crucial forecast of sample sizes required for

differing levels of PRS accuracy. Our projection analyses indicated that achieving an AUC of

0.70 would approach the maximized prediction potential of the PRS, given the estimated genetic

variance explained by GWAS chip variants. To reach this level of accuracy, a future study would

need to include 55,000 cases with a 1:10 case-control ratio. Notably, accessing large biobanks

with publicly available controls could reduce the number of required cases[54].–These projections

offer a strategic framework for planning and designing future genetic studies on lung cancer,

establishing clear benchmarks for PRS model performance, which is essential for the scientific

community in advancing genetic risk prediction.

701   Our study has several limitations. First, it focuses solely on the genetic susceptibility of

LUAD without incorporating additional questionnaire-based risk factors, especially familly

history. However, leveraging the largest GWAS dataset available, our primary goal was to

develop the most effective PRS model, which can be integrated with other risk indicators in

future studies. Second, our projections are based on single-ancestry PRS models and do not fully

account for the complexities of multi-ancestry approaches, such as varying sample sizes and

genetic correlations across populations. Third, our validation cohort, derived from the FLCCA

and covering various East Asian regions, relied on Taiwanese incidence data for absolute risk

estimations. Lastly, while genome-wide PRS models like LDpred2 and CT-SLEB demonstrated

strong performance, their reliance on nearly one million SNPs poses challenges related to

overfitting and clinical feasibility. Future work should aim to optimize PRS models by

prioritizing key loci while maintaining predictive power.

In summary, our study evaluates various PRS models to capture the genetic

predisposition to LUAD among never-smoking East Asian individuals. It extends beyond risk

prediction by estimating both 10-year and cumulative lifetime absolute risks, and by projecting

the sample sizes required for future GWAS to refine the predictive power of PRSs in future

GWAS. Additionally, we quantify the phenotypic variance captured by PRSs across different

sample sizes. Despite advancements in using PRS for smoking cessation trials[55], its

implementation for never-smokers in clinical settings has been limited, presenting a significant

area for research. Future studies are crucial to further improve these PRS models, aiming to

enhance genetic risk predictions while integrating a wider array of risk factors. Such efforts will

develop more accurate and comprehensive risk models for LUAD in never-smoking individuals

across different populations.

Data availability statement

All data supporting the findings described in this paper are available in the paper and in the Supplementary Information and from the corresponding author or as otherwise indicated upon request. The individual genotype data for the FLCCA data are in dbGaP phs000716.v1.p1 (Genome-Wide Association Study of Lung Cancer Susceptibility in Never-Smoking Women in Asia). For the NCC and ACC studies, please contact Kouya Shiraishi at kshirais@ncc.go.jp or Takashi Kohno at tkkohno@ncc.go.jp for summary statistics. The GWAS data for the European populations contributing to this study are available at dbGap under accession phs000877.v1.p1 (Transdisciplinary Research Into Cancer of the Lung (TRICL), https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000876.v2.p1), phs001273.v3.p2 (Oncoarray Consortium, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001273.v3.p2). To gain access to all data in dbGaP cited in this paper, please apply for dbGaP Authorized Access. GWAS data for the European populations contributing to this study are available under accession phs000877.v1.p1 (ILLCO), phs001273.v1.p1 (OncoArray).

Code Availability

Methods implemented and their corresponding repositories include: SCT and LDpred2 at https://github.com/privefl/bigsnpr, PRS-CSx at https://github.com/getian107/PRScsx. CT-SLEB at https://github.com/andrewhaoyu/CTSLEB, and GENESIS at https://github.com/yandorazhang/GENESIS.

PLINK: https://www.cog-genomics.org/plink/1.9.

Most of our statistical analyses were performed using the following R packages: ggplot2 v.3.3.3, dplyr v.1.0.4, data.table v.1.13.6, iCARE v.1.30.0

https://github.com/KevinWFred/PRS_EASLC

Funding

Female Lung Cancer Consortium in Asia (NCI): This study was supported by a Grant-in-Aid for

Scientific Research on Priority Areas from the Ministry of Education, Science, Sports, Culture

and Technology of Japan, a Grant-in- Aid for the Third Term Comprehensive 10-Year Strategy

for Cancer Control from the Ministry Health, Labor and Welfare of Japan, by Health and Labor

Sciences Research Grants for Research on Applying Health Technology from the Ministry of

Health, Labor and Welfare of Japan, by the National Cancer Center Research and Development

Fund, the National Research Foundation of Korea (NRF) grant funded by the Korea government

(MEST) (grant No. 2011-0016106), a grant of the National Project for Personalized Genomic

Medicine, Ministry for Health & Welfare, Republic of Korea (A111218-11-GM04), the Program

for Changjiang Scholars and Innovative Research Team in University in China (IRT_14R40 to

K.C.), the National Science & Technology Pillar Program (2011BAI09B00), MOE 111 Project

(B13016), the National Natural Science Foundation of China (No. 30772531, and 81272618),

Guangdong Provincial Key Laboratory of Lung Cancer Translational Medicine (No.

2012A061400006), Special Fund for Research in the Public Interest from the National Health

and Family Planning Commission of PRC (No. 201402031), and the Ministry of Science and

Technology, Taiwan (MOST 103-2325-B-400-023 & 104-2325-B-400-012). The Japan Lung

Cancer Study (JLCS) was supported in part by the Practical Research for Innovative Cancer

Control from Japan Agency for Medical Research and Development (15ck0106096h0002) and

the Management Expenses Grants from the Government to the National Cancer Center (26-A-1)

for Biobank. BioBank Japan was supported by the Ministry of Education, Culture, Sports,

Sciences and Technology of the Japanese government. The Japan Public Health Center-based

prospective Study (the JPHC Study) was supported by the National Cancer Center Research and

Development Fund (23-A- 31[toku], 26-A-2, 29-A-4, 2020-J-4, and 2023-J-4) (since 2011) and a

Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan

(from 1989 to 2010). The Taiwan GELAC Study (Genetic Epidemiological Study for Lung

AdenoCarcinoma) was sup- ported by grants from the National Research Program on Genomic

Medicine in Taiwan (DOH99-TD-G-111-028), the National Research Program for

Biopharmaceuticals in Taiwan (MOHW 103-TDUPB-211-144003, MOST 103-2325-B-400-023)

and the Bioinformatics Core Facility for Translational Medicine and Biotechnology

Development (MOST 104-2319-B-400-002). This work was also supported by the Jinan Science

Research Project Foundation (201102051), the National Key Scientific and Technological

Project (2011ZX09307-001-04), the National Natural Science Foundation of China

(No.81272293), the State Key Program of National Natural Science of China (81230067), the

National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP)

(No. NRF- 2014R1A2A2A05003665), Sookmyung Women's University Research Grants, Korea

(1-1603-2048), Agency for Science, Technology and Research (A*STAR), Singapore and the

US National Institute of Health Grant (1U19CA148127-01). The overall GWAS project was

supported by the intramural program of the US National Institutes of Health/National Cancer

Institute. The following is a list of grants by study center: SKLCS (Y.T.K.)—National Research

Foundation of Korea (NRF) grant funded by the Korea government (MEST) (2011-0016106).

(J.C.) – This work was supported by a grant from the National R&D Program for Cancer

Control, Ministry of Health &Welfare, Republic of Korea (grant no. 0720550-2). (J.S.S) – grant

number is A010250. WLCS (T.W.)—National Key Basic Research and Development Program

(2011CB503800). SLCS (B.Z.)—National Nature Science Foundation of China (81102194).

Liaoning Provincial Department of Education (LS2010168). China Medical Board (00726). GDS

(Y.L.W.)—Foundation of Guangdong Science and Technology Department (2006B60101010,

2007A032000002, 2011A030400010). Guangzhou Science and Information Technology Bureau

(2011Y2-00014). Chinese Lung Cancer Research Foundation, National Natural Science

Foundation of China (81101549). Natural Science Foundation of Guangdong Province

(S2011010000792). TLCS (K.C., B.Q)—Program for Changjiang Scholars and Innovative

Research Team in University (PCSIRT), China (IRT1076). Tianjin Cancer Institute and Hospital.

National Foundation for Cancer Research (US). FLCS (J.C.W., D.R., L.J.)—Ministry of Health

(201002007). Ministry of Science and Technology (2011BAI09B00). National S&T Major

Special Project (2011ZX09102-010-01). China National High-Tech Research and Development

Program (2012AA02A517, 2012AA02A518). National Science Foundation of China

(30890034). National Basic Research Program (2012CB944600). Scientific and Technological

Support Plans from Jiangsu Province (BE2010715). NLCS (H.S.)—China National High-Tech

Research and Development Program Grant (2009AA022705). Priority Academic Program

Development of Jiangsu Higher Education Institution. National Key Basic Research Program

Grant (2011CB503805). GEL-S (A.S.)—National Medical Research Council Singapore grant

(NMRC/0897/2004, NMRC/1075/2006). (J.Liu)—Agency for Science, Technology and

Research (A*STAR) of Singapore. GELAC (C.A.H.)—National Research Program on Genomic

Medicine in Taiwan (DOH98-TDG-111-015). National Research Program for

Biopharmaceuticals in Taiwan (DOH 100- TD-PB-111-TM013). National Science Council,

Taiwan (NSC 100- 2319-B-400-001). YLCS (Q.L.)—Supported by the intramural pro- gram of

U.S. National Institutes of Health, National Cancer Institute. SWHS (W.Z., W-H.C., N.R.)—The

work was supported by a grant from the National Institutes of Health (R37 CA70867, UM1

CA182910) and the National Cancer Institute intramural research program, including NCI

Intramural Research Program contract (N02 CP1101066). JLCS (K.M., T.K.)—Grants-in-Aid

from the Ministry of Health, Labor, and Welfare for Research on Applying Health Technology

and for the 3rd-term Comprehensive 10-year Strategy for Cancer Control; by the National

Cancer Center Research and Development Fund; by Grant-in-Aid for Scientific Research on

Priority Areas and on Innovative Area from the Ministry of Education, Science, Sports, Culture

and — Technology of Japan. (W.P.)—NCI R01-CA121210. HKS (J.W.)— General Research

Fund of Research Grant Council, Hong Kong (781511M). The Environment and Genetics in

Lung Cancer Etiology (EAGLE), Prostate, Lung, Colon, Ovary Screening Trial (PLCO), and

Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) studies were supported by the

Intramural Research Program of the National Institutes of Health, National Cancer Institute

(NCI), Division of Cancer Epidemiology and Genetics. ATBC was also supported by U.S. Public

Health Service contracts (N01-CN-45165, N01-RC-45035, and N01-RC-37004) from the NCI.

PLCO was also supported by individual contracts from the NCI to the University of Colorado

Denver (NO1-CN-25514), Georgetown University (NO1-CN-25522), the Pacific Health

Research Institute (NO1-CN-25515), the Henry Ford Health System (NO1-CN-25512), the

University of Minnesota, (NO1-CN- 25513), Washington University (NO1-CN-25516), the

University of Pittsburgh (NO1-CN-25511), the University of Utah (NO1-CN- 25524), the

Marshfield Clinic Research Foundation (NO1-CN- 25518), the University of Alabama at

Birmingham (NO1-CN- 75022), Westat, Inc. (NO1-CN-25476), and the University of California,

Los Angeles (NO1-CN-25404). The Carotene and Retinol Efficacy Trial (CARET) is funded by

the National Cancer Institute, National Institutes of Health through grants U01-CA063673,

UM1-CA167462, and U01-CA167462. The Cancer Prevention Study-II (CPS-II) Nutrition

Cohort was supported by the American Cancer Society. The NIH Genes, Environment and

Health Initiative (GEI) partly funded DNA extraction and statis- tical analyses (HG-06-033-NCI-

01 and RO1HL091172-01), genotyping at the Johns Hopkins University Center for Inherited

Disease Research. This research was supported by the National Research Foundation of Korea

(NRF) grant funded by the Korea government (MSIT) (No. 2020R1A2C4002236)

Female Lung Cancer Consortium in Asia (Tianjin): Tianjin Science and Technology Committee

Foundation, 18YFZCSY00520.

Female Lung Cancer Consortium in Asia (Taiwan): The Ministry of Health and Welfare grants

DOH97-TD-G-111-028 (ISC), DOH98-TD-G-111-017 (ISC), DOH99-TD-G-111-014 (ISC);

DOH97-TD-G-111-026 (CAH), DOH98-TD-G-111-015 (CAH), DOH99-TD-G-111-028

(CAH); National Health Research Institutes grants NHRI-PH-110-GP-01, NHRI-PH-110-GP-03;

and the Ministry of Science and Technology grants MOST108-2314-B-400-038(CAH),

MOST109-2740-B-400-002(CAH), MOST 111-2740-B-400-002 (CAH), MOST 111-2314-B-

400-020 (CAH).

The GWAS of lung cancer in European never smokers was supported by NIH R01 CA149462

(OYG).

OncoArray study in Europeans: The OncoArray data and analysis from INTEGRAL-ILCCO

were supported by NIH U19 CA203654, and U19 CA148127. The data harmonization for

ILCCO was supported by Canadian Institute for Health Research (CIHR) Canada Research Chair

to R.J.H, and CIHR FDN 167273).

European never-smoking lung cancer study: CIA is a Research Scholar of the Cancer Prevention

Institute of Texas (CPRIT) and supported by CPRIT grant RR170048.

Taiwan eQTL study: This study was supported by the Ministry of Health and Welfare grants

DOH97-TD-G-111-028 (ISC), DOH98-TD-G-111-017 (ISC), DOH99-TD-G-111-014 (ISC);

DOH97-TD-G-111-026 (CAH), DOH98-TD-G-111-015 (CAH), DOH99-TD-G-111-028

(CAH); National Health Research Institutes grants NHRI-PH-110-GP-01, NHRI-PH-110-GP-03;

and the Ministry of Science and Technology grants MOST108-2314-B-400-038(CAH),

MOST109-2740-B-400-002(CAH).

This research was also supported by the National Natural Science Foundation of China

(82388102)

B.B., K.W., J.C., J.S. N.R., Q.L. and H.Z. are supported by NIH intramural Research Program.

N.C. is supported by NIH grant 1R01HG010480. P.Y. is supported by Mayo Clinic Foundation

Research Funds, NIH-CA77118 and CA80127. G.L. is supported is supported by the Alan

Brown Chair and Lusi Wong Fund of the Princess Margaret Cancer Foundation. D.C.C is

supported by U01CA209414. O.Y.G. is supported by NIH R01 CA231141.

This research was supported [in part] by the Intramural Research Program of the National
Institutes of Health (NIH). The contributions of the NIH authors were made as part of their
official duties as NIH federal employees, are in compliance with agency policy requirements,
and are considered works of the United States Government. However, the findings and
conclusions presented in this paper are those of the authors and do not necessarily reflect the
views of the NIH or the U.S. Department of Health and Human Services.

895
896

897   **Conflict of Interest**

898   The authors declare no competing interests.

900   **Acknowledgements**

902   We gratefully acknowledge the important historical contribution that the following individuals
903   made to the development and success of this long-term collaboration:
904

Minsun Song, PhD, Department of Statistics & Research Institute of Natural Sciences,
Sookmyung Women's University, Seoul, Republic of Korea;

Michiaki Kubo, PhD, Laboratory for Genotyping Development, RIKEN Center for Integrative
Medical Sciences, Yokohama, , Japan;

Haruhiko Nakayama, PhD, Department of Thoracic Surgery, Kanagawa Cancer Center,
Yokohama, Japan;

Yuichiro Ohe, PhD,Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan;

Jian Su, PhD, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China;

Ying-Huang Tsai, PhD, Department of Respiratory Therapy, Chang Gung University, Taoyuan, Taiwan;

Ming-Shyan Huang, PhD, Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University and Kaohsiung Medical University, Kaohsiung, Taiwan;

Kun-Chieh Chen, PhD, Department of Internal Medicine, Division of Pulmonary Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan;

Biyun Qian, PhD, Department of Epidemiology and Biostatistics, Key Laboratory of Prevention and Control of Human Major Diseases of the Ministry of Education, Key Laboratory of Molecular Cancer Epidemiology of Tianjin, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China;

Chen Wu, PhD, Department of Etiology & Carcinogenesis and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;

Margaret R Spitz, PhD, Department of Medicine, Section of Epidemiology and Population Science, Institute for Clinical and Translational Research, Houston, TX, USA;

Mikael Johansson, PhD, Department of Radiation Sciences, Umeå University, Umeå, Sweden;

Jae Sook Sung, PhD, Department of Internal Medicine, Division of Oncology/Hematology, College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea;

Yoo Jin Jung, PhD, Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea;

Huan Guo, PhD, Department of Occupational and Environmental Health and Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;

Bin Zhu, PhD, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA;

Li Liu, PhD, Department of Oncology, Cancer Center, Union Hospital, Huazhong University of Science and Technology, Wuhan, China;

Ying Chen, PhD, Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore;

Jun Suk Kim, PhD, Department of Internal Medicine, Division of Medical Oncology, College of Medicine, Korea University Guro Hospital, Seoul , Republic of Korea;

Ho-Il Yoon, PhD,Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea;

Ping Xu, PhD,Department of Oncology, Wuhan Iron and Steel (Group) Corporation Staff-Worker Hospital , Wuhan, China;

Chih-Liang Wang, PhD, Department of Thoracic Medicine, Division of Pulmonary Oncology and Interventional Bronchoscopy, Chang Gung Memorial Hospital, Taoyuan, Taiwan;

Wei-Yen Lim, PhD, Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore;

Hongyan Chen, PhD, Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China;

Li Jin, PhD, Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China;

Shengchao A. Li, MS, Division of Cancer Epidemiology and Genetics, National Cancer Institute, , Rockville, MD, USA;

Gening Jiang, PhD, Shanghai Pulmonary Hospital, Shanghai, China;

Ke Fei, PhD, Shanghai Pulmonary Hospital, Shanghai, , China;

References

1. Bray, F. *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* **68**, 394–424 (2018).

2. Sun, S., Schiller, J. H. & Gazdar, A. F. Lung cancer in never smokers--a different disease. *Nat. Rev. Cancer* **7**, 778–790 (2007).

3. Cheng, T. Y. D. *et al.* The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. *J. Thorac. Oncol.* **11**, 1653–1671 (2016).

4. Byun, J. *et al.* 'Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer'. *Nat Genet* **54**, 1167 (2022).

5. Landi, M. T. *et al.* Tracing lung cancer risk factors through mutational signatures in never-smokers. *Am. J. Epidemiol.* **190**, 962–976 (2021).

6. Corrales, L. *et al.* Lung cancer in never smokers: The role of different risk factors other than tobacco smoking. *Crit. Rev. Onco. Hematol.* **148**, (2020).

7. Sisti, J. & Boffetta, P. What proportion of lung cancer in never-smokers can be attributed to known risk factors? *Int. J. Cancer* **131**, 265–275 (2012).

8. Shi, J. *et al.* Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. *Nature Commun.* **14**, (2023).

9. Dai, J. *et al.* Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. *Lanet. Respir. Med.* **7**, 881–891 (2019).

10. Seow, W. J. *et al.* Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. *Hum. Mol. Genet.* **26**, 454–465 (2017).

11. Lan, Q. *et al.* Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. *Nat. Genet.* **44**, 1330–1335 (2012).

12. Li, Y. *et al.* Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. *Lanet Oncol.* **11**, 321–330 (2010).

13. Hung, R. J. *et al.* Lung cancer risk in never-smokers of European descent is associated with genetic variation in the 5p15.33 TERT-CLPTM1Ll region. *J. Thorac Oncol .* **14**, 1360–1369 (2019).

14. Lebrett, M. B. *et al.* Validation of lung cancer polygenic risk scores in a high-risk case-control cohort. *Genet. Med.* **25**, (2023).

15. Hung, R. J. *et al.* Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model. *Cancer Res.* **81**, 1607–1615 (2021).

16. Linder, J. E. *et al.* Returning integrated genomic risk and clinical recommendations: The eMERGE study. *Genet. Med.* **25**, (2023).

17. Hao, L. *et al.* Development of a clinical polygenic risk score assay and reporting workflow. *Nat. Med.* **28**, 1006–1013 (2022).

18. Shieh, Y. *et al.* Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. *J. Natl. Cancer Inst.* **109**, (2017).

19. Kachuri, L. *et al.* Principles and methods for transferring polygenic risk scores across global populations. *Nat. Rev. Genet.* **25**, 8–25 (2024).

20. Jin, J. *et al.* MUSSEL: Enhanced Bayesian polygenic risk prediction leveraging
information across multiple ancestry groups. *Cell Genom.* **4**, (2024).
21. Zhang, J. *et al.* An ensemble penalized regression method for multi-ancestry polygenic
risk prediction. *Nat. Commun.* **15**, 1–14 (2024).
22. Hou, K. *et al.* Admix-kit: an integrated toolkit and pipeline for genetic analyses of
admixed populations. *Bioinformatics* **40**, (2024).
23. Hoggart, C. J. *et al.* BridgePRS leverages shared genetic effects across ancestries to
increase polygenic risk score portability. *Nat. Genet.* **56**, 180–186 (2024).
24. Zhang, H. *et al.* A new method for multiancestry polygenic prediction improves
performance across diverse populations. *Nat. Genet.* **55**, 1757–1768 (2023).
25. Zhou, G., Chen, T. & Zhao, H. SDPRX: A statistical method for cross-population
prediction of complex traits. *Am. J. Hum. Genet* . **110**, 13–22 (2023).
26. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat.*
Genet. **54**, 573–580 (2022).
27. Shi, J. *et al.* Genome-wide association study of lung adenocarcinoma in East Asia and
comparison with a European population. *Nature Communications 2023 14:1* **14**, 1–17
(2023).
28. Dong, J. *et al.* Association analyses identify multiple new lung cancer susceptibility loci
and their interactions with smoking in the Chinese population. *Nat Genet* **44**, 895 (2012).
29. Wang, C. *et al.* Analyses of rare predisposing variants of lung cancer in 6,004 whole
genomes in Chinese. *Cancer Cell* **40**, 1223-1239.e6 (2022).
30. Dai, J. *et al.* Risk loci identification and polygenic risk score in prediction of lung cancer:
a large-scale prospective cohort study in Chinese. *Lancet Respir Med* **7**, 881 (2019).
31. Hu, Z. *et al.* A genome-wide association study identifies two new lung cancer
susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. *Nat Genet* **43**, 792–796
(2011).
32. Chen, Z. *et al.* China Kadoorie Biobank of 0.5 million people: survey methods, baseline
characteristics and long-term follow-up. *Int J Epidemiol* **40**, 1652–1666 (2011).
33. Walters, R. G. *et al.* Genotyping and population characteristics of the China Kadoorie
Biobank. *Cell Genomics* **3**, 100361 (2023).
34. Purcell, S. M. *et al.* Common polygenic variation contributes to risk of schizophrenia and
bipolar disorder. *Nature* **460**, 748–752 (2009).
35. Chang, C. C. *et al.* Second-generation PLINK: Rising to the challenge of larger and richer
datasets. *Gigascience* **4**, 7 (2015).
36. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. *Bioinformatics*
36, 5424–5431 (2021).
37. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
38. Hung, R. J. *et al.* Assessing Lung Cancer Absolute Risk Trajectory based on a Polygenic
Risk Model. *Cancer Res* **81**, 1607 (2021).
39. Hung, R. J. *et al.* LUNG CANCER RISK IN NEVER SMOKERS OF EUROPEAN
DESCENT IS ASSOCIATED WITH GENETIC VARIATION IN THE 5P15.33 TERT-
CLPTM1L REGION. *J Thorac Oncol* **14**, 1360 (2019).
40. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74
(2015).

41.   Foucher, Y. *et al.* RISCA: Causal Inference and Prediction in Cohort-Based Analyses. *R*
1006   *package version 1.01* Preprint at https://cran.r-project.org/package=RISCA (2020).
1007   42.   Pal Choudhury, P. *et al.* iCARE: An R package to build, validate and apply absolute risk
1008   models. *PLoS One* **15**, e0228198 (2020).
1009   43.   Chien, L. H. *et al.* Predicting lung cancer occurrence in never-smoking females in Asia:
1010   TNSF-SQ, a prediction model. *Cancer Epidemiology Biomarkers and Prevention* **29**,
1011   452–459 (2020).
1012   44.   Zhang, Y., Qi, G., Park, J. H. & Chatterjee, N. Estimation of complex effect-size
1013   distributions using summary-level statistics from genome-wide association studies across
1014   32 complex traits. *Nat. Genet.* **50**, 1318–1326 (2018).
1015   45.   Choudhury, P. P. *et al.* iCARE: An R package to build, validate and apply absolute risk
1016   models. *PLoS One* **15**, (2020).
1017   46.   Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for
1018   complex traits. *Nature* **570**, 514–518 (2019).
1019   47.   Duncan, L. *et al.* Analysis of polygenic risk score usage and performance in diverse
1020   human populations. *Nat. Commun.* **10**, (2019).
1021   48.   Kullo, I. J. *et al.* Polygenic scores in biomedical research. *Nat. Rev. Genet.* **23**, 524–532
1022   (2022).
1023   49.   Martin, A. R. *et al.* Clinical use of current polygenic risk scores may exacerbate health
1024   disparities. *Nat. Genet.* **51**, 584–591 (2019).
1025   50.   Chang, G. C. *et al.* Low-dose CT screening among never-smokers with or without a
1026   family history of lung cancer in Taiwan: a prospective cohort study. *Lancet Respir Med*
1027   **12**, 141–152 (2024).
1028   51.   Wei, X. *et al.* Development and evaluation of a polygenic risk score for lung cancer in
1029   never-smoking women: A large-scale prospective Chinese cohort study. *Int. J. Cancer*
1030   **154**, 807–815 (2024).
1031   52.   Krist, A. H. *et al.* Screening for Lung Cancer: US Preventive Services Task Force
1032   Recommendation Statement. *JAMA - Journal of the American Medical Association* **325**,
1033   962–970 (2021).
1034   53.   Blechter, B. *et al.* Polygenic risk score, environmental tobacco smoke, and risk of lung
1035   adenocarcinoma in never-smoking women in Taiwan. *JAMA Netw. Open* **6**, E2339254
1036   (2023).
1037   54.   Katki, H. A. *et al.* Increase in power by obtaining 10 or more controls per case when type-
1038   1 error is small in large-scale association studies. *BMC Med. Res. Methodol.* **23**, (2023).
1039   55.   Chen, T. *et al.* Genomic insights for personalised care in lung cancer and smoking
1040   cessation: motivating at-risk individuals toward evidence-based health practices.
1041   *EBioMedicine* **110**, 105441 (2024).
1042

1043

1044

Table 1. Prediction performance of different methods for generating polygenic risk scores for lung cancer in never-smoking East Asian populations in FLCCA.

Model type	Number of SNPs	OR (95% CI)[a]	AUC (95% CI)[b]
Single-ancestry method[c]			
PRS-25[d]	25	1.52 (1.43, 1.61)	0.618 (0.613, 0.636)
PRS-CT	8	1.37 (1.29, 1.46)	0.591 (0.585, 0.609)
LDpred2 PRS	942,591	1.62 (1.52, 1.73))	0.629 (0.618, 0.641)
PRS-EUR 128[e]	128 (109 available)	0.97 (0.91, 1.03)	0.489 (0.477, 0.501)
Multi-ancestry method[f]			
LDpred2 PRS + PRS-EUR 128	942,681	1.62 (1.52, 1.72)	0.629 (0.617, 0.640)
PRS-CSx	1,031,786	1.67 (1.57, 1.78)	0.637 (0.625, 0.647)
CT-SLEB	2,127,229	1.71 (1.61, 1.82)	0.640 (0.629, 0.653)

Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; AUC, area under the curve; PC, principal component; CT, clumping and thresholding

[a] ORs are provided per one unit standard deviation of PRS.

[b] Adjusted for age (continuous) and first 10 principal components.

[c] Sample size for single-ancestry PRS methods included 3,564 cases and 16,238 controls of East Asian ancestry for training, 2,219 cases and 2,272 controls of East Asian ancestry for tuning and 2,219 cases and 2,272 controls of East Asian ancestry for validation.

[d] SNPs that reached genome-wide significance in Shi et al., 2023.

[e] SNPs obtained from genome-wide association study conducted in individuals with European ancestry (Hung et al., 2021, Cancer Res.).

[f] Sample size for multi-ancestry PRS methods included 3,564 cases and 16,238 controls of East Asian ancestry, as well as 2,058 cases and 5,575 controls of European ancestry for training, 2,219 cases and 2,272 controls of East Asian ancestry for tuning and 2,219 cases and 2,272 controls of East Asian ancestry for validation.

Table 2. Prediction performance of different methods for generating polygenic risk scores for lung cancer in never-smoking East Asian populations from Nanjing, China.

Model type	Number of SNPs	Overall		Male		Female	
		OR (95% CI)[a]	AUC (95% CI)[b]	OR (95% CI)[a]	AUC (95% CI)[b]	OR (95% CI)[a]	AUC (95% CI)[b]
Single-ancestry method[c]							
PRS-25[d]	25	1.51 (1.40, 1.63)	0.615 (0.592, 0.638)	1.50 (1.32, 1.73)	0.616 (0.576, 0.654)	1.52 (1.38, 1.67)	0.602 (0.575, 0.632)
PRS-CT	8	1.33 (1.23, 1.43)	0.574 (0.549, 0.600)	1.40 (1.23, 1.60)	0.593 (0.553, 0.637)	1.30 (1.19, 1.42)	0.561 (0.529, 0.59)
LDpred2 PRS	942,591	1.80 (1.67, 1.95)	0.657 (0.635, 0.678)	1.91 (1.66, 2.21)	0.669 (0.633, 0.705)	1.77 (1.61, 1.95)	0.645 (0.615, 0.672)
PRS-EUR 128[e]	128 (109 available)	1.04 (0.96, 1.12)	0.507 (0.481, 0.533)	1.05 (0.92, 1.20)	0.521 (0.473, 0.561)	1.03 (0.94, 1.12)	0.506 (0.473, 0.538)
Multi-ancestry method[f]							
LDpred2 PRS + PRS-EUR 128	942,681	1.79 (1.65, 1.94)	0.656 (0.632, 0.675)	1.91 (1.66, 2.21)	0.668 (0.631, 0.700)	1.75 (1.59, 1.93)	0.642 (0.617, 0.67)
PRS-CSx	1,031,786	1.81 (1.67, 1.96)	0.654 (0.630, 0.676)	1.87 (1.63, 2.16)	0.659 (0.619, 0.694)	1.81 (1.64, 1.99)	0.645 (0.613, 0.672)
CT-SLEB	2,127,229	1.78 (1.64, 1.92)	0.653 (0.631, 0.675)	1.71 (1.49, 1.96)	0.653 (0.618, 0.692)	1.85 (11.68, 2.04)	0.649 (0.623, 0.676)

Abbreviations: SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; AUC, area under the curve; PC, principal component; CT, clumping and thresholding

[a] ORs are provided per one unit standard deviation of PRS.

[b] Adjusted for age (continuous) and first 10 principal components.

[c] Sample size for single-ancestry PRS methods included 3,564 cases and 16,238 controls of East Asian ancestry for training, 2,219 cases and 2,272 controls of East Asian ancestry for tuning and 1,643 never-smoking LUAD cases (473 male; 1,170 female) and 2,235 never-smoking controls (795 male; 1,440 female) of East Asian ancestry for validation.

[d] SNPs that reached genome-wide significance in Shi et al., 2023.

[e] SNPs obtained from genome-wide association study conducted in individuals with European ancestry (Hung et al., 2021, Cancer Res.).

[f] Sample size for multi-ancestry PRS methods included 3,564 cases and 16,238 controls of East Asian ancestry, as well as 2,058 cases and 5,575 controls of European ancestry for training, 2,219 cases and 2,272 controls of East Asian ancestry for tuning and 1,643 never-smoking LUAD cases (473 male; 1,170 female) and 2,235 never-smoking controls (795 male; 1,440 female) of East Asian ancestry for validation.

Table 3. Genetic variance in East Asian lung cancer among never smokers explained by LDpred2 PRS

Sample size[a]	Genetic variance of PRS[b]	Proportion of all-GWAS variants genetic variance explained by PRS[c]	Proportion of Familial risk explained by PRS[d]
Current	0.201	26.6%	16.5%
35,000 cases	0.437	57.9%	35.8%
55,000 cases	0.540	71.5%	44.3%

[a] *Sample Size*: The current sample comprises 3,564 cases and 16,238 controls. Future projections assume a 1:10 case-control ratio for sample sizes of 35,000 and 55,000 cases. Genetic variance projections for the LDpred2 PRS are based on the GENESIS method, originally designed for the CT method (refer to Nat. Genet. 50, 1318-1326 (2018)), extended to include LDpred2 by modeling the variance ratio between LDpred2 and CT (**Supplementary Methods**).

[b] *Genetic Variance of PRS*: This corresponds to the heritability on the frailty scale, assuming a polygenic log-additive model underpins this relationship. It quantifies the proportion of the phenotype variation that can be attributed to genetic factors in the context of PRS.

[c] *Proportion of Genetic Variance from All-GWAS Variants Explained by PRS*: This represents the variance of all genome-wide imputable variants as established through LD-score regression (refer to Nat. Genet. 47, 291-5 (2015) and Nat. Genet. 47, 1236-41 (2015)). On the frailty scale, the genetic variance of all GWAS variants is calculated as $\sigma^2_{GWAS} = Var(\sum_{m=1}^{M} \beta_m G_m)$, where G_m is the standardized genotype for the mth SNP, β_m is the true log odds ratio for the mth SNP and M is the total number of causal SNPs among the GWAS variants. For East Asian never smokers, the estimated genetic variance of all GWAS variants is 0.755.

[d] Proportion of Familial Risk Explained by PRS: This calculates the familial risk in terms of genetic variance using the formula $\lambda_s^2 = \exp(\sigma^2)$, where λ_s is the familial risk when a first-order sibling has the disease, and σ^2 is the genetic variance on frailty-scale. Further details of this calculation can be found in Nat. Genet. 31, 33-36 (2002). For lung cancer in East Asian never-smokers, the familial risk is a 1.84-fold increase, and the genetic variance of all GWAS variants, as estimated through LD-score regression, explains 61.9% of this increased familial relative risk.

Figure Legends

Figure 1. Overview of data structure, polygenic risk score (PRS) development, validation and application. Summary statistics from East Asian genome-wide association studies (GWAS) were used to develop single-ancestry PRS using methods such as a simple PRS constructed using 25 SNPs that have previously reached genome-wide significance (i.e., $P<5x10^{-8}$) (PRS-25), a PRS using the clumping and thresholding (CT) method (PRS-CT) incorporating 8 SNPs, and a PRS using a genome-wide Bayesian-based approach, LDpred2 (LDpred2 PRS) incorporating

close to a million SNPs. For the multi-ancestry PRS development, we also used summary statistics from European (EUR) GWAS, applying the PRS-CSx method that leveraged genome-wide association summary statistics for close to a million SNPs with a Bayesian continuous shrinkage prior to model SNP effect sizes across populations, as well as CT-SLEB method, which enhances the standard CT methods with a two-dimensional approach to select SNPS for East Asian PRS construction by incorporating over 2 million SNPs. Tuning and validation of each PRS was conducted in an independent East Asian individual-level data. Relative risk per PRS quantile was calculated as an odds ratio (OR) with the middle quantile (40th to 60th percentile) set as the reference, and the area under the receiver operating curve (AUC) was estimated for each PRS. CT-SLEB PRS was used to estimate 10-year and lifetime cumulative absolute risk, and PRS-CT and PRS-LDpred2 were used for sample size projection.

Figure 2. Relative risk estimated for quantiles of each polygenic risk score (PRS) and lung adenocarcinoma in the validation dataset of women with East Asian ancestry, treating the 40th to 60th percentile as the references. Odds ratios of PRS per standard deviation (SD) and 95% confidence intervals are shown for (A) the single-ancestry 25 SNP polygenic risk score, PRS-25 (A), (B) Clumping and thresholding method, PRS-CT, (C) Bayesian-based genome-wide approach, LDpred2 PRS, and (D) multi-ancestry approach, CT-SLEB.

Figure 3. Association between polygenic risk score (PRS) and lung adenocarcinoma by age groups. (A) Odds ratios (ORs) per standard deviation (SD) of the PRS and 95% confidence intervals, and (B) ORs for individuals in the upper 90th percentile of the PRS.

A

B

Figure 4. Lifetime cumulative and 10-year absolute risk of developing lung adenocarcinoma. (A) Lifetime (age 30-80) cumulative risk and (B) 10-year absolute risk of developing lung adenocarcinoma in never-smoking women in East Asia by percentiles of the CT-SLEB polygenic risk score (PRS). Absolute risks were calculated using the iCARE package[42], based on Taiwan's age-specific incidence and mortality data, and the PRS relative risks, as described in the Methods section.

A

B

Figure 5. Projected area under the receiver operating characteristic curve (AUC) of polygenic risk scores (PRS) built using genome-wide association studies (GWAS) with varying sample sizes for lung adenocarcinoma in never-smoking East Asian women. (A) AUC values for PRS-CT and LDpred2 PRS with case-to-control ratios of 1:1 and 1:10. (B) AUC values for LDpred2 PRS across case-to-control ratios of 1:1, 1:2, 1:3, 1:4, 1:5, and 1:10

Author contributions

B.B., N.R., Q.L. and H.Z. organized and designed the study. B.B., X.W., H.Z. carried out the statistical analyses with supervision from N.R., Q.L. and H.Z. C.K. conducted the validation analyses in CKB. J.D., Y.W., T. Q. conducted the validation analyses in NJLCC. B.B., X.W., Q.L. N.R. and H.Z. wrote the first draft. B.B., X.W., C.K., J.D. Q.L. N.R. and H.Z. review and edit the draft. Q.L., M.T.L., B.A.B., W.H., N.E.C., BT.J., M.Song, H.P., D.A., C.C.C., L.B., M.Y., A.H., B.H., J.Liu, B.Zhu, S.I.B., C.K., K.Wyatt, S.A.L., A.Chao, J.F.F.J., S.J.C., N.R., Z.Wang, C.L., J.C., C.W., W.T., D.Lin, SJ.A., XC.Z., J.S., YL.W., M.P.W., L.P.C., J.C.M.H., V.H.F.L., Z.H., K.M., J.Y..P., Jia.Liu, HS.J., J.E..C., Y.Y.C., H.N.K., MH.S., SS.K., YC.K., IJ.O., S.W.S., HI.Y., Y.T.K., YC.H., J.H.K., Y.H.K., J.S..S., Y.J..J., K.H.P., C.H.K., J.S.K., I.K.P., B..S., Jie.L, Z.W., S.C., J.Y., JC.W., Y.Y., YB.X., YT.G., D.L., J.Y.Y.W., H.C., L..J., J.Z., G.J., K..F., Z.Y., B.Z., W.W., P.G., Q.H., X.L., Y.R., A.S., Y.L., Y.C., WY.L., W.Z., XO.S., Q.C., G.Y., B.Q., T.W., H.G., L..L., P.X., F.W., G.W., J.X., J.L., R.CH.V., B.B., H.D.III.H., J.Wang, A.D.L..S., J.KC.C., V.L.S., K.C., H.Z., H.D., C.A.H., TY.C., LH.C..., IS.C., CY.C., S.S.J ., CH.C., GC.C., CF.H., YH.T., WC.W., KY.C., MS.H., WC.S., YM.C., CL.W., KC.C., CJ.Y., HH.H., FY.T.., HC.L., CJ.C., PC.Y., K.Shiraishi, T.K., H.K., S.M., H.H., K.Goto, Y.Ohe, S.W., Y.Yatabe, M.T., R.Hamamoto, A.Takahashi, Y.Momozawa, M.Kubo, Y.K., Y.D., Y.Miyagi, H.N., T.Y., N.S., M.I., M.H., Y.N., K.Takeuchi, K.W., K.Matsuda, Y.Murakami, K.S., K.T., Y.O., M.S., H.Suzuki, A.G., Y.M., T.H., M.K., K.O., H.S., J.D., H.M., M.Z., R.J.H., S.L., A.T., C.C., S.E.B., M.Johansson, A.R., H.Bö., HE.W., D.C., G.R., S.A., P.B., J.MK., J.K.F., S.S.S., L.L.M., O.M.., H.Bö., G.L., A.A., L.A.K., S.ZN., K.G., M.J., A.C., JM.Y., P.L., M.B.S., M.C.A., C.I.A., A.G.S., R.H., M.R.S., O.Y.G., I.P.G., X.W., P.Y. conducted epidemiology studies and contributed samples to GWAS and/or conducted initial genotyping. All authors reviewed and approved the final review of the manuscript.